Literature DB >> 12897196

Ribozyme-mediated revision of RNA and DNA.

Meredith B Long1, J P Jones, Bruce A Sullenger, Jonghoe Byun.   

Abstract

Mesh:

Substances:

Year:  2003        PMID: 12897196      PMCID: PMC166303          DOI: 10.1172/JCI19386

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  26 in total

1.  Self-splicing of the Tetrahymena intron from mRNA in mammalian cells.

Authors:  M Hagen; T R Cech
Journal:  EMBO J       Date:  1999-11-15       Impact factor: 11.598

2.  A reverse transcriptase/maturase promotes splicing by binding at its own coding segment in a group II intron RNA.

Authors:  H Wank; J SanFilippo; R N Singh; M Matsuura; A M Lambowitz
Journal:  Mol Cell       Date:  1999-08       Impact factor: 17.970

3.  RNA and protein catalysis in group II intron splicing and mobility reactions using purified components.

Authors:  R Saldanha; B Chen; H Wank; M Matsuura; J Edwards; A M Lambowitz
Journal:  Biochemistry       Date:  1999-07-13       Impact factor: 3.162

4.  Design of highly specific cytotoxins by using trans-splicing ribozymes.

Authors:  B G Ayre; U Köhler; H M Goodman; J Haseloff
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

5.  Spliceosome-mediated RNA trans-splicing as a tool for gene therapy.

Authors:  M Puttaraju; S F Jamison; S G Mansfield; M A Garcia-Blanco; L G Mitchell
Journal:  Nat Biotechnol       Date:  1999-03       Impact factor: 54.908

6.  Rules for DNA target-site recognition by a lactococcal group II intron enable retargeting of the intron to specific DNA sequences.

Authors:  G Mohr; D Smith; M Belfort; A M Lambowitz
Journal:  Genes Dev       Date:  2000-03-01       Impact factor: 11.361

7.  Trans-splicing ribozymes for targeted gene delivery.

Authors:  U Köhler; B G Ayre; H M Goodman; J Haseloff
Journal:  J Mol Biol       Date:  1999-02-05       Impact factor: 5.469

8.  Probing the interplay between the two steps of group I intron splicing: competition of exogenous guanosine with omega G.

Authors:  P P Zarrinkar; B A Sullenger
Journal:  Biochemistry       Date:  1998-12-22       Impact factor: 3.162

9.  Evaluating group I intron catalytic efficiency in mammalian cells.

Authors:  M B Long; B A Sullenger
Journal:  Mol Cell Biol       Date:  1999-10       Impact factor: 4.272

10.  Induction of wild-type p53 activity in human cancer cells by ribozymes that repair mutant p53 transcripts.

Authors:  T Watanabe; B A Sullenger
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-18       Impact factor: 11.205

View more
  8 in total

Review 1.  Targeted genetic repair: an emerging approach to genetic therapy.

Authors:  Bruce A Sullenger
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

2.  In vivo excision of a single targeted nucleotide from an mRNA by a trans excision-splicing ribozyme.

Authors:  Dana A Baum; Stephen M Testa
Journal:  RNA       Date:  2005-05-04       Impact factor: 4.942

3.  Trans-splicing group I intron targeting hepatitis C virus IRES mediates cell death upon viral infection in Huh7.5 cells.

Authors:  Pruksa Nawtaisong; Mark E Fraser; James R Carter; Malcolm J Fraser
Journal:  Virology       Date:  2015-04-07       Impact factor: 3.616

4.  Targeted gene disruption in Francisella tularensis by group II introns.

Authors:  Stephen A Rodriguez; Greg Davis; Karl E Klose
Journal:  Methods       Date:  2009-05-04       Impact factor: 3.608

5.  Targeted inactivation of francisella tularensis genes by group II introns.

Authors:  Stephen A Rodriguez; Jieh-Juen Yu; Greg Davis; Bernard P Arulanandam; Karl E Klose
Journal:  Appl Environ Microbiol       Date:  2008-02-29       Impact factor: 4.792

6.  Targeting of highly conserved Dengue virus sequences with anti-Dengue virus trans-splicing group I introns.

Authors:  James R Carter; James H Keith; Pradip V Barde; Tresa S Fraser; Malcolm J Fraser
Journal:  BMC Mol Biol       Date:  2010-11-15       Impact factor: 2.946

7.  Variables and strategies in development of therapeutic post-transcriptional gene silencing agents.

Authors:  Jack M Sullivan; Edwin H Yau; Tiffany A Kolniak; Lowell G Sheflin; R Thomas Taggart; Heba E Abdelmaksoud
Journal:  J Ophthalmol       Date:  2011-06-30       Impact factor: 1.909

8.  Lariat capping as a tool to manipulate the 5' end of individual yeast mRNA species in vivo.

Authors:  Nicolai Krogh; Max Pietschmann; Manfred Schmid; Torben Heick Jensen; Henrik Nielsen
Journal:  RNA       Date:  2017-02-03       Impact factor: 4.942

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.